Back

Inhibition of Factor XI using a GalNAc-siRNA RBD5049: a novel antithrombotic drug with high potency and long duration

28 August 2023 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Oral anticoagulation in patients with venous thromboembolism or left ventricular thrombus Anticoagulants ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Li-Ming Gan

Early Clinical Development, Research and Early Development, CVRM, BioPharmaceuti, Gothenburg (Sweden)

6 More presentations in this session

Presentation thumbnail
Baseline characteristics and outcomes of extended oral anticoagulant treatment in patients with venous thrombosis: a retrospective cohort study in France
Mr R. Subash (Surrey, GB)
Abstract Slides Video
Presentation thumbnail
Comparative effectiveness and safety of apixaban and low-molecular weight heparin among patients with venous thromboembolism and active cancer in an extended treatment setting
Doctor A. Cohen (London, GB)
Abstract Slides Video
Presentation thumbnail
The effect of DOAC-Stop on lupus anticoagulant testing in patients with pulmonary embolism receiving direct oral anticoagulants
Professor A. Undas (Krakow, PL)
Abstract Slides Video
Presentation thumbnail
Anticoagulant therapy beyond primary treatment among active cancer and non-cancer patients with venous thromboembolism in the United States
Doctor A. Cohen (London, GB)
Abstract Slides Video
Presentation thumbnail
Clinical characteristics and outcomes of super-low-dose edoxaban of 15 mg in patients with acute venous thromboembolism: insight from the COMMAND VTE Registry-2
Doctor K. Kaneda (Kyoto, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Oral anticoagulation in patients with venous thromboembolism or left ventricular thrombus

The Event

Event poster

ESC Congress 2023

28 August 2023 16:15 CET
You may be interested in
thumbnail
Congress Presentation
First-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of RBD4059, a GalNAc-siRNA drug targeting coagulation factor XI (FXI), in healthy subjects
thumbnail
Congress Presentation
RNA-based therapy in anticoagulation
thumbnail
Congress Presentation
Preclinical characterisation and first-in-human results on the tolerability and pharmacodynamic effect of REGN9933, a monoclonal antibody targeting the factor XI/activated factor XI apple 2 domain

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources